A diagnostic assay for the AKT1 E17K mutation will facilitate assessment of clinical activity of the pan-AKT inhibitor AZD5363 in advanced cancer patients whose tumor harbors this oncogenic mutation. This evidence concerns the gene AKT1 and neoplasm.